Literature DB >> 30144543

Role of activating transcription factor 3 and its interacting proteins under physiological and pathological conditions.

M Rohini1, A Haritha Menon1, N Selvamurugan2.   

Abstract

Activating transcription factor 3 (ATF3) is a stress-responsive factor that belongs to the activator protein 1 (AP-1) family of transcription factors. ATF3 expression is stimulated by various factors such as hypoxia, cytokines, and chemotherapeutic and DNA damaging agents. Upon stimulation, ATF3 can form homodimers or heterodimers with other members of the AP-1 family to repress or activate transcription. Under physiological conditions, ATF3 expression is transient and plays a pivotal role in controlling the expression of cell-cycle regulators and tumor suppressor, DNA repair, and apoptosis genes. However, under pathological conditions such as those during breast cancer, a sustained and prolonged expression of ATF3 has been observed. In this review, the structure and function of ATF3, its posttranslational modifications (PTM), and its interacting proteins are discussed with a special emphasis on breast cancer metastasis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATF3; Breast cancer; Runx2

Mesh:

Substances:

Year:  2018        PMID: 30144543     DOI: 10.1016/j.ijbiomac.2018.08.107

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  22 in total

1.  ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.

Authors:  Ravyn M Duncan; Leticia Reyes; Katelyn Moats; Reeder M Robinson; Sara A Murphy; Balveen Kaur; Holly A F Stessman; Nathan G Dolloff
Journal:  Cancer Res       Date:  2020-06-19       Impact factor: 12.701

2.  A Seven-NF-κB-Related Gene Signature May Distinguish Patients with Ulcerative Colitis-Associated Colorectal Carcinoma.

Authors:  Chao-Yi Ge; Li-Yuan Wei; Yu Tian; Hua-Hong Wang
Journal:  Pharmgenomics Pers Med       Date:  2020-12-02

3.  Induction of heparanase 2 (Hpa2) expression by stress is mediated by ATF3.

Authors:  Ibrahim Knani; Preeti Singh; Miriam Gross-Cohen; Sharon Aviram; Neta Ilan; Ralph D Sanderson; Ami Aronheim; Israel Vlodavsky
Journal:  Matrix Biol       Date:  2021-11-20       Impact factor: 11.583

4.  Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.

Authors:  Zhe Sha; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-19       Impact factor: 11.205

5.  ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia.

Authors:  Daniela Di Marcantonio; Esteban Martinez; Joice S Kanefsky; Jacklyn M Huhn; Rashid Gabbasov; Anushk Gupta; John J Krais; Suraj Peri; YinFei Tan; Tomasz Skorski; Adrienne Dorrance; Ramiro Garzon; Aaron R Goldman; Hsin-Yao Tang; Neil Johnson; Stephen M Sykes
Journal:  Mol Cell       Date:  2021-06-02       Impact factor: 19.328

6.  Silencing ATF3 Might Delay TBHP-Induced Intervertebral Disc Degeneration by Repressing NPC Ferroptosis, Apoptosis, and ECM Degradation.

Authors:  Yongjin Li; Dayu Pan; Xuke Wang; Zhenxin Huo; Xiaojing Wu; Jianhua Li; Jiasong Cao; Haiwei Xu; Lilong Du; Baoshan Xu
Journal:  Oxid Med Cell Longev       Date:  2022-04-15       Impact factor: 7.310

7.  Activating transcription factor 3 inhibits endometrial carcinoma aggressiveness via JunB suppression.

Authors:  Fangyuan Wang; Jingjing Li; Haixia Wang; Fan Zhang; Jin Gao
Journal:  Int J Oncol       Date:  2020-06-19       Impact factor: 5.650

8.  Screening of Cellular Stress Responses Induced by Ambient Aerosol Ultrafine Particle Fraction PM0.5 in A549 Cells.

Authors:  Pavlína Šimečková; Soňa Marvanová; Pavel Kulich; Lucie Králiková; Jiří Neča; Jiřina Procházková; Miroslav Machala
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

9.  Epstein-Barr virus-positive gastric cancer involves enhancer activation through activating transcription factor 3.

Authors:  Yuta Asakawa; Atsushi Okabe; Masaki Fukuyo; Wenzhe Li; Eriko Ikeda; Yasunobu Mano; Sayaka Funata; Hiroe Namba; Takahiro Fujii; Kazuko Kita; Keisuke Matsusaka; Atsushi Kaneda
Journal:  Cancer Sci       Date:  2020-03-20       Impact factor: 6.716

10.  Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease.

Authors:  Mohammed A Assiri; Hadi R Ali; John O Marentette; Youngho Yun; Juan Liu; Matthew D Hirschey; Laura M Saba; Peter S Harris; Kristofer S Fritz
Journal:  Hum Genomics       Date:  2019-12-10       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.